Nucleic Acid Proficiency Standards for cfDNA Diagnostics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for non-invasive prenatal genetic diagnostics and cancer cell DNA detection using cell-free DNA are complex and prone to errors due to the scarcity of naturally occurring samples and variability, necessitating the development of standardized testing procedures that are challenging to implement effectively.
Innovation Solution
The creation of nucleic acid proficiency testing standards comprising nucleosomal nucleic acid preparations from different cell sources, allowing for the simulation of various fetal or tumor DNA fractions, enabling the production of large quantities of genetic testing standards that mimic natural cell-free DNA samples, thereby facilitating standardized testing and improving diagnostic accuracy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If naturally occurring cell-free DNA samples are used for diagnostic testing, then the testing can be performed with real clinical samples, but the scarcity and variability of such samples make it difficult to establish standardized testing procedures
Solution Approach 1:
The patent creates artificial cell-free DNA standards that copy the essential characteristics of natural cell-free DNA samples. These synthetic standards contain nucleosomal DNA fragments with size distributions and sequence compositions that mimic authentic clinical samples, enabling standardized testing without relying on scarce natural samples. The copying principle allows laboratories to use these replicated standards for proficiency testing and method validation.
2Adaptability or versatility
If naturally occurring samples are used for proficiency testing, then the testing reflects real clinical conditions, but the variability between samples complicates the establishment of consistent analysis standards
Solution Approach 1:
The artificial cell-free DNA standards incorporate specific local qualities that match clinical samples where needed. The standards contain nucleosomal DNA with authentic sequence variations, fragment size distributions, and compositional characteristics at critical locations. This localized matching of qualities ensures clinical relevance while maintaining overall consistency across different batches of the same standard.
Solution Approach 2:
The patent employs parameter changes to create a series of artificial standards with different controlled characteristics. By systematically varying parameters such as DNA fragment size distribution, nucleosomal composition ratios, and sequence diversity while controlling other factors, the invention generates multiple standardized samples that reflect different clinical scenarios without the uncontrolled variability of natural samples.
3Loss of information
If complex diagnostic methods are used to detect cell-free DNA, then comprehensive genetic information can be obtained, but the complexity increases the risk of errors and reduces testing reliability
Solution Approach 1:
The artificial cell-free DNA standards are prepared in advance with known compositions and characteristics. By having pre-characterized standards with defined nucleosomal DNA content, fragment size distributions, and sequence compositions available before clinical testing, laboratories can validate their diagnostic methods and establish performance benchmarks without the complexity of handling variable natural samples during actual diagnostics.
Data Source
AI summary
Embodiments of the invention include methods and compositions for producing standards for noninvasive prenatal genetic diagnostics and for the detection and monitoring of cancer. The compositions can include a plurality of different nucleosomal DNA fragments derived from either primary cells or cell lines and can include one or more synthetic oligonucleotides. The amount of the different nucleosomal DNA fragments can be varied so as to simulate naturally occurring cell free DNA samples obtained from the blood of the pregnant woman or naturally occurring cell free DNA samples obtained from the blood of cancer patients.